Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;10(10):2819-33.
doi: 10.4161/hv.29984.

Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis

Alexander Domnich  1 , Donatella Panatto, Eva Klementievna Arbuzova, Alessio Signori, Ulderico Avio, Roberto Gasparini, Daniela Amicizia
Affiliations
Review

Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis

Alexander Domnich et al. Hum Vaccin Immunother. 2014.

Abstract

Tick-borne encephalitis (TBE) virus, which is usually divided into European, Far Eastern and Siberian subtypes, is a serious public health problem in several European and Asian countries. Vaccination is the most effective measure to prevent TBE; cross-subtype protection elicited by the TBE vaccines is biologically plausible since all TBE virus subtypes are closely related. This manuscript systematically explores available data on the cross-subtype immunogenicity elicited by the currently available Western vaccines based on the European subtype. Completed immunization course of 3 doses of both Western vaccines determined very high seroconversion/seropositivity rates against both Far Eastern and Siberian subtypes among previously flavivirus-naïve subjects. All but one study found no statistically significant difference in titers of neutralizing antibodies against strains belonging to homologous and heterologous subtypes. Pooled analysis of randomized controlled trials on head-to-head comparison of immunogenicity of Western and Russian TBE vaccines did not reveal differences in seroconversion rates against Far Eastern isolates in either hemagglutination inhibition (risk ratio = 0.98, p = 0.83) or enzyme-linked immunosorbent (risk ratio = 0.95, p = 0.44) assays after 2 vaccine doses. This suggests that, in regions where a heterogeneous TBE virus population circulates, vaccines based on the European subtype may be used alongside vaccines based on the Far Eastern subtype. Studies on the field effectiveness of TBE vaccines and investigation of vaccination failures, especially in countries where different subtypes co-circulate, will further elucidate TBE vaccination-induced cross-subtype protection.

Keywords: C, capside; CEE, Central European encephalitis; CI, confidence interval; E, envelope; ELISA, enzyme-linked immunosorbent assay; European subtype; FSME, Frühsommer-Meningoenzephalitis [German] (tick-borne encephalitis); Far Eastern subtype; GMT, geometric mean titer; HI, hemagglutination inhibition; IFA, indirect immunofluorescence; IPVE, Institute of Poliomyelitis and Viral Encephalitis; IgG, Immunoglobulin G; M, membrane; NR, not reported; NS, non-structural; NT, neutralization test; RCT, randomized controlled trial; RNA, ribonucleic acid; RR, risk ratio; RSSE, Russian spring summer encephalitis virus; SCR, seroconversion rate; SD, standard deviation; SMD, standardized mean difference; SPR, seropositivity rate; Siberian subtype; TBE; TBE, tick-borne encephalitis; TBEV, tick-borne encephalitis virus; TBEV-Eu, European subtype of TBEV; TBEV-FE, Far Eastern subtype of TBEV; TBEV-Sib, Siberian subtype of TBEV; VIEU, Vienna unit; WHO, World Health Organization; cross-protection; cross-subtype immunogenicity; d, day; prM, pre-membrane; tick-borne encephalitis; vaccines; we: week; y, year; μNT, microneutralization test.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of the study selection process. Since 2 studies41,42 used a commercial hemagglutination inhibition (HI) kit based on strain 139, 1 study17 used an enzyme-linked immunosorbent assay (ELISA) kit based on strain 205 and another study49 used both commercial kits, 2 separate meta-analyses on the basis of serological assay were performed.
Figure 2.
Figure 2.
Forest plot of seroconversion rates on hemagglutination inhibition assay by means of commercial kit one month after 2 doses of FSME-Immun and Russian vaccines: random effects model.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization (WHO) Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol Rec 2011; 86:241-56; PMID:21661276 - PubMed
    1. Amicizia D, Domnich A, Panatto D, Lai PL, Cristina ML, Avio U, Gasparini R. Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines. Hum Vaccin Immunother 2013; 9:1163-71; PMID:23377671; http://dx.doi.org/10.4161/hv.23802 - DOI - PMC - PubMed
    1. International Committee on Taxonomy of Viruses Virus taxonomy: 2011 release. Available at: http://www.ictvonline.org/virusTaxonomy.asp?version=2011&bhcp=1 Accessed: November 17, 2014
    1. McMinn PC. The molecular basis of virulence of the encephalitogenic flaviviruses. J Gen Virol 1997; 78(Pt 11):2711-22; PMID:9367356 - PubMed
    1. Fritz R, Orlinger KK, Hofmeister Y, Janecki K, Traweger A, Perez-Burgos L, Barrett PN, Kreil TR. Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes. Vaccine 2012; 30:1165-9; PMID:22178103; http://dx.doi.org/10.1016/j.vaccine.2011.12.013 - DOI - PubMed

MeSH terms